当前位置: 首页 >> 检索结果
3561. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection.
作者: Mahmoud Abu-Amara.;Orlando Cerocchi.;Gurtej Malhi.;Suraj Sharma.;Colina Yim.;Hemant Shah.;David K Wong.;Harry L A Janssen.;Jordan J Feld.
来源: Gut. 2016年65卷8期1347-58页
Patients with chronic hepatitis B (CHB) infection are at an increased risk of developing hepatocellular carcinoma (HCC). Risk scores have been developed in Asian populations to predict HCC risk over time.
3562. Clinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow-up of 2 years.
作者: Yuki B Werner.;Guido Costamagna.;Lee L Swanström.;Daniel von Renteln.;Pietro Familiari.;Ahmed M Sharata.;Tania Noder.;Guido Schachschal.;Jan F Kersten.;Thomas Rösch.
来源: Gut. 2016年65卷6期899-906页
The recently developed technique for peroral endoscopic myotomy (POEM) has been shown to be effective in several short-term studies. Longer term outcome data are largely non-existent.
3563. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
作者: F Kastelein.;S H van Olphen.;E W Steyerberg.;M C W Spaander.;M J Bruno.; .
来源: Gut. 2016年65卷4期548-54页
Endoscopic surveillance for Barrett's oesophagus (BO) is under discussion given the overall low incidence of neoplastic progression and lack of evidence that it prevents advanced oesophageal adenocarcinoma (OAC). The aim of this study was to evaluate the impact of endoscopic BO surveillance on tumour stage and survival of patients with neoplastic progression.
3564. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
作者: Shomron Ben-Horin.;Miri Yavzori.;Itai Benhar.;Ella Fudim.;Orit Picard.;Bella Ungar.;SooYoung Lee.;SungHwan Kim.;Rami Eliakim.;Yehuda Chowers.
来源: Gut. 2016年65卷7期1132-8页
The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima (CT-P13) with the originator drug Remicade is still unknown.
3565. Identification and genetic manipulation of human and mouse oesophageal stem cells.
作者: Youngtae Jeong.;Horace Rhee.;Shanique Martin.;Daniel Klass.;Yuan Lin.;Le Xuan Truong Nguyen.;Weiguo Feng.;Maximilian Diehn.
来源: Gut. 2016年65卷7期1077-86页
Human oesophageal stem cell research is hampered by the lack of an optimal assay system to study self-renewal and differentiation. We aimed to identify and characterise human and mouse oesophageal stem/progenitor cells by establishing 3-dimensional organotypic sphere culture systems for both species.
3567. Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence.
作者: Monika Schaubeck.;Thomas Clavel.;Jelena Calasan.;Ilias Lagkouvardos.;Sven Bastiaan Haange.;Nico Jehmlich.;Marijana Basic.;Aline Dupont.;Mathias Hornef.;Martin von Bergen.;André Bleich.;Dirk Haller.
来源: Gut. 2016年65卷2期225-37页
Dysbiosis of the intestinal microbiota is associated with Crohn's disease (CD). Functional evidence for a causal role of bacteria in the development of chronic small intestinal inflammation is lacking. Similar to human pathology, TNF(deltaARE) mice develop a tumour necrosis factor (TNF)-driven CD-like transmural inflammation with predominant ileal involvement.
3569. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
作者: Raymond Kwok.;Kai Chow Choi.;Grace Lai-Hung Wong.;Yuying Zhang.;Henry Lik-Yuen Chan.;Andrea On-Yan Luk.;Sally She-Ting Shu.;Anthony Wing-Hung Chan.;Ming-Wai Yeung.;Juliana Chung-Ngor Chan.;Alice Pik-Shan Kong.;Vincent Wai-Sun Wong.
来源: Gut. 2016年65卷8期1359-68页
Type 2 diabetes is an important risk factor for non-alcoholic fatty liver disease (NAFLD), but current guidelines provide conflicting recommendations on whether diabetic patients should be screened for NAFLD. We therefore studied the strategy of screening diabetic patients by FibroScan.
3570. Detection of precancerous gastric lesions and gastric cancer through exhaled breath.
作者: Haitham Amal.;Marcis Leja.;Konrads Funka.;Roberts Skapars.;Armands Sivins.;Guntis Ancans.;Inta Liepniece-Karele.;Ilze Kikuste.;Ieva Lasina.;Hossam Haick.
来源: Gut. 2016年65卷3期400-7页
Timely detection of gastric cancer (GC) and the related precancerous lesions could provide a tool for decreasing both cancer mortality and incidence.
3571. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.
作者: Filip Baert.;Venkateswarlu Kondragunta.;Steven Lockton.;Niels Vande Casteele.;Scott Hauenstein.;Sharat Singh.;Konstantinos Karmiris.;Marc Ferrante.;Ann Gils.;Séverine Vermeire.
来源: Gut. 2016年65卷7期1126-31页
Data on immunogenicity to adalimumab (ADL) therapy in patients with IBD is limited. We performed additional analyses on the Karmiris cohort using the homogeneous mobility shift assay (HMSA) focusing on the inter-relationship of serum ADL concentration, antibodies-to-adalimumab (ATA), inflammatory markers and sustained response.
3572. Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities.
作者: Charlotte Hedin.;Christopher J van der Gast.;Geraint B Rogers.;Leah Cuthbertson.;Sara McCartney.;Andrew J Stagg.;James O Lindsay.;Kevin Whelan.
来源: Gut. 2016年65卷6期944-53页
To determine the existence of mucosal dysbiosis in siblings of patients with Crohn's disease (CD) using 454 pyrosequencing and to comprehensively characterise and determine the influence of genotypical and phenotypical factors, on that dysbiosis. Siblings of patients with CD have elevated risk of developing CD and display aspects of disease phenotype, including faecal dysbiosis. Whether the mucosal microbiota is disrupted in these at-risk individuals is unknown.
3573. Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer.
作者: Elise Punkenburg.;Tina Vogler.;Maike Büttner.;Kerstin Amann.;Max Waldner.;Raja Atreya.;Benjamin Abendroth.;Jonas Mudter.;Susanne Merkel.;Eike Gallmeier.;Stefan Rose-John.;Markus F Neurath.;Kai Hildner.
来源: Gut. 2016年65卷7期1139-50页
IBDs have an increased risk for development of colorectal cancer (CRC). Here, we aimed at the characterisation of the functional role of Th17-associated transcription factors in sporadic and colitis-associated colon cancer in vivo.
3574. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.3575. Genetic variants of lipase activity in chronic pancreatitis.
作者: Holger Kirsten.;Markus Scholz.;Peter Kovacs.;Harald Grallert.;Annette Peters.;Konstantin Strauch.;Josef Frank.;Marcella Rietschel.;Markus M Nöthen.;Heiko Witt.;Jonas Rosendahl.
来源: Gut. 2016年65卷1期184-5页 3576. Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.
作者: Alexander Hamm.;Hans Prenen.;Wouter Van Delm.;Mario Di Matteo.;Mathias Wenes.;Estelle Delamarre.;Thomas Schmidt.;Jürgen Weitz.;Roberta Sarmiento.;Angelo Dezi.;Giampietro Gasparini.;Françoise Rothé.;Robin Schmitz.;André D'Hoore.;Hannes Iserentant.;Alain Hendlisz.;Massimiliano Mazzone.
来源: Gut. 2016年65卷6期990-1000页
Cancer immunology is a growing field of research whose aim is to develop innovative therapies and diagnostic tests. Starting from the hypothesis that immune cells promptly respond to harmful stimuli, we used peripheral blood monocytes in order to characterise a distinct gene expression profile and to evaluate its potential as a candidate diagnostic biomarker in patients with colorectal cancer (CRC), a still unmet clinical need.
3577. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
作者: Xiao Xu.;Di Lu.;Qi Ling.;Xuyong Wei.;Jian Wu.;Lin Zhou.;Sheng Yan.;Liming Wu.;Lei Geng.;Qinghong Ke.;Feng Gao.;Zhenhua Tu.;Weilin Wang.;Min Zhang.;Yan Shen.;Haiyang Xie.;Wenshi Jiang.;Haibo Wang.;Shusen Zheng.
来源: Gut. 2016年65卷6期1035-41页
Liver transplantation is an optimal radical therapy for selected patients with hepatocellular carcinoma. The stringent organ allocation system driven by the Milan criteria has been challenged by alternative sets of expanded criteria. Careful analysis is needed to prove that the Milan criteria can be expanded safely and effectively.
3579. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.
作者: Hui Ling.;Karen Pickard.;Cristina Ivan.;Claudio Isella.;Mariko Ikuo.;Richard Mitter.;Riccardo Spizzo.;Marc Bullock.;Cornelia Braicu.;Valentina Pileczki.;Kimberly Vincent.;Martin Pichler.;Verena Stiegelbauer.;Gerald Hoefler.;Maria I Almeida.;Annie Hsiao.;Xinna Zhang.;John Primrose.;Graham Packham.;Kevin Liu.;Krishna Bojja.;Roberta Gafà.;Lianchun Xiao.;Simona Rossi.;Jian H Song.;Ivan Vannini.;Francesca Fanini.;Scott Kopetz.;Patrick Zweidler-McKay.;Xuemei Wang.;Calin Ionescu.;Alexandru Irimie.;Muller Fabbri.;Giovanni Lanza.;Stanley R Hamilton.;Ioana Berindan-Neagoe.;Enzo Medico.;Alex Mirnezami.;George A Calin.;Milena S Nicoloso.
来源: Gut. 2016年65卷6期977-989页
MicroRNA (miRNA) expression profile can be used as prognostic marker for human cancers. We aim to explore the significance of miRNAs in colorectal cancer (CRC) metastasis.
3580. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
作者: Young-Suk Lim.;Byung Chul Yoo.;Kwan Soo Byun.;So Young Kwon.;Yoon Jun Kim.;Jihyun An.;Han Chu Lee.;Yung Sang Lee.
来源: Gut. 2016年65卷6期1042-51页
Little clinical data are available regarding the optimal treatment of patients who harbour adefovir-resistant HBV.
|